Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of Diluted vs. Undiluted Intravenous DA-5217 in Healthy Adults
NCT07027982Phase 1Completed
- Sponsor
- Dong-A ST
- Start
- Jul 2025
- Primary completion
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of DA-5217 in upper gastrointestinal bleeding (UGIB) (2 arms), sponsored by Dong-A ST. Primary endpoint: Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration. Started Jul 2025; status: completed.
02
Drugs
DA-5217
03
Conditions
upper gastrointestinal bleeding (UGIB)
Beyond the preview
Go deeper on NCT07027982.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07027982.